COMMUNIQUÉS West-GlobeNewswire

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
02/04/2026
LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced [...]
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
02/04/2026
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
02/04/2026
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
Catalyst MedTech Announces Acquisition of X3D
02/04/2026
Expands OEM Platform and Strengthens Leadership in Nuclear Medicine Imaging PITTSBURGH, April 02, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, today [...]
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
02/04/2026
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group [...]
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
02/04/2026
New regional partnership strengthens Nanox ’s presence and service support across outpatient imaging settings in Colorado , Wyoming and the western parts of Kansas and Nebraska Agreement aligns with Nanox’s strategy to [...]
Sienna Announces First Quarter 2026 Results Release Date and Conference Call
02/04/2026
MARKHAM, Ontario, April 02, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 first quarter results after market close on Tuesday, May 5 [...]
Sienna Completes Acquisition in Greater Toronto Area
02/04/2026
MARKHAM, Ontario, April 02, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed acquisition of The Bartlett, a 129 [...]
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02/04/2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting [...]
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor
02/04/2026
The new extension brings Commure’s Ambient AI to every text field, replacing legacy dictation systems with a single, seamless voice platform. MOUNTAIN VIEW, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Commure today [...]
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
New system centralizes at-home DNA testing, biological age assessment, and lab diagnostics into a unified reporting experience ST. PETERSBURG, FL, April 02, 2026 (GLOBE NEWSWIRE) -- MyGevity announced the nationwide [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
02/04/2026
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/ [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
02/04/2026
NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrations NTR-1011 displayed a predictable pharmacokinetic ( [...]
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
02/04/2026
Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on- [...]
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 [...]

Pages